



(11) **EP 1 956 029 A1**

(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 158(3) EPC

(43) Date of publication:
13.08.2008 Bulletin 2008/33

(21) Application number: **06822567.1**

(22) Date of filing: **30.10.2006**

(51) Int Cl.:
C07K 14/47 (2006.01) **C07K 16/18** (2006.01)
G01N 33/53 (2006.01)

(86) International application number:
PCT/JP2006/321610

(87) International publication number:
WO 2007/063664 (07.06.2007 Gazette 2007/23)

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**

(30) Priority: **29.11.2005 JP 2005344630**

(71) Applicant: **Nagasaki University
Nagasaki-Shi
Nagasaki , 8528521 (JP)**

(72) Inventors:
• **KONDO, Takahito
Nagasaki-shi, Nagasaki 852- 8521 (JP)**

- **IHARA, Yoshihito
Nagasaki-shi, Nagasaki 852-8521 (JP)**
- **URATA, Yoshishige
Nagasaki-shi, Nagasaki 852-8521 (JP)**
- **GOTO, Shinji
Nagasaki-shi, Nagasaki 852-8521 (JP)**
- **KONO, Takaaki
Nagasaki-shi, Nagasaki 852-8521 (JP)**

(74) Representative: **Duckworth, Timothy John
J.A. Kemp & Co.,
14 South Square,
Gray's Inn
London WC1R 5JJ (GB)**

(54) **VASCULAR AGING-PREDICTING FACTOR AND UTILIZATION OF THE SAME**

(57) A predicting factor for vascular aging and an examination method for an early-stage lesion resulting from vascular aging are provided. Specifically, a predicting factor for vascular aging comprising a human apolipoprotein B100 having a glutathionylated thiol group; a method of examining a lesion resulting from vascular aging contain measurement of a human apolipoprotein B100 having a glutathionylated thiol group in the blood

sample; an antibody specifically recognizing an apolipoprotein B100 having a glutathionylated thiol group; a diagnostic agent or a diagnostic kit for an early-stage lesion resulting from vascular aging containing an antibody recognizing a human apolipoprotein B100 having a glutathionylated thiol group, are provided.

EP 1 956 029 A1

Description**Technical Field**

5 [0001] The present invention relates to a predicting factor for vascular aging and utilization thereof. In particular, the present invention relates to a predicting factor for vascular aging using glutathionylation of a specific thiol group of a human apolipoprotein B100 as an index and a detection method thereof.

Background Art

10 [0002] In the metabolic syndrome which is expected to spread more and more in the future, diabetes mellitus (impaired glucose tolerance), hypertension, hyperlipidemia, obesity, and the like which are underlying diseases for the metabolic syndrome act commonly as a promoting factor for vascular aging. Vascular aging causes cardiac infarction and cerebral infarction through development of arterial sclerosis, arterial occlusion or the like. However, objective indices available for the vascular aging are those obtained by morphological measurements such as ultrasonic diagnostics of the carotid artery, and a simple measurement method using serum of a patient as the sample has not been established yet. That is, factors predicting onset of cerebral infarction, cardiac infarction, obstructive arteriosclerosis and the like which are critical and irreversible tissue damages subsequent to the metabolic syndrome have not been established to date.

15 [0003] Oxidative stress is thought to be one of the causes for many disorders including lifestyle-related diseases, and aging. Oxidative stress is also known to act as a promoting factor for vascular aging. As an oxidative stress marker, immunological determination of protein carbonylation and a TBAS method for determining lipoperoxidation are well known conventionally. However, these methods involve problems associated with specificity and reproducibility when serum is used as the sample. Meanwhile, in recent years, methods using a specific antibody against oxidative denaturation of lipid and protein fractions in LDL have been developed. The oxidative denaturation shows a process in which proteins and lipids undergo irreversible denaturation and degradation and is known to be associated with the advancement of atherosclerosis. However, the oxidative denaturation may not be considered in part as an index of earlier indication of vascular aging.

20 [0004] A thiol group of proteins is oxidatively modified in a nonenzymatic fashion by oxidative stress, which causes intramolecularly cross-linked protein and inactivation of enzyme proteins, thus proceeding to functional changes of proteins. A thiol group is sometimes oxidized to cause irreversible modification. S-glutathionylation (protein-SSG, glutathionylation) plays a role of protecting functions and structures of proteins from such an irreversible oxidative modification. In other words, hydrogen peroxide modifies a thiol group of a cysteine of a protein and promotes an irreversible denaturation process with sulfenic acid (-SOH) and further with sulfinic acid (-SO₂H) and sulfonic acid (-SO₃H). Modification of a thiol group with glutathione is a reversible change and is also regulated by concentrations of reduced glutathione (GSH) and oxidized glutathione (GSSG). This is referred to as "redox". Redox is an important mechanism that is associated with the function or activity of living organisms or cells and controls cellular differentiation and proliferation, and cellular death. In other words, the oxidative modification of a thiol group of a protein indicates an imbalance in the redox state of a living organism. Failure of redox results in apoptosis of tissue cells, and further, remodeling, and is considered to be deeply involved in the mechanism of vascular aging.

25 [0005] Methods for measuring a thiol group of a protein modified with glutathione have been reported so far.

30 1) An immunological method using an anti-glutathionylated bovine albumin antibody (non-patent reference 1). This method involves problems associated with specificity and measurement sensitivity, and is not suited for practical application.

35 2) A method using a biotinylated glutathione S-transferase (non-patent reference 2). This is an application of the fact that the glutathione S-transferase recognizes a glutathionylated thiol group through an enzyme reaction, but this method involves many problems associated with sensitivity and specificity.

40 [non-patent reference 1] Heille, OP et al., Eur. J. Neurosci., vol. 6, p. 793-804 (1994)

45 [non-patent reference 2] Cheng, G et al., Archiv. Biochem. Biophys., vol. 435, p. 42-49 (2005)

Disclosure of the Invention**Problems to be Solved by the Invention**

50 [0006] An object of the present invention is to provide a biomarker useful for prediction of vascular aging and an examination method for a lesion resulting from vascular aging using the biomarker as an index.

Means for Solving the Problems

[0007] The inventors of the present invention made intensive studies and examinations continuously in order to solve the above-mentioned problems, paid attention particularly to an apolipoprotein B100 localized in low density lipoprotein (LDL), identified the domain of a glutathionylated thiol group in advance, then produced a specific antibody against the site, and established a highly sensitive immunoassay to complete the present invention.

[0008] That is, the present invention provides the following:

[1] A predicting factor for vascular aging comprising an apolipoprotein B100 having a glutathionylated thiol group, or a part thereof which includes the glutathionylated region and consists of at least 10 amino acid residues,

[2] The predicting factor according to the above-mentioned [1], wherein the apolipoprotein B100 and a part thereof include at least an amino acid sequence represented by SEQ ID NO: 2, wherein the glutathionylated region is a thiol group of a cysteine in the amino acid sequence,

[3] A method for examining a lesion resulting from vascular aging comprising measurement of an apolipoprotein B100 having a glutathionylated thiol group using a biological sample,

[4] The method according to the above-mentioned [3], wherein the biological sample is blood,

[5] The method according to the above-mentioned [3] or [4], wherein the lesion resulting from vascular aging is accompanied by a disorder selected from the group consisting of diabetes mellitus, cerebrovascular disorder, cardiovascular disorder, obstructive arteriosclerosis, dementia, atherosclerosis, hypertension, obesity, and the like,

[6] An antibody specifically recognizing an apolipoprotein B100 having a glutathionylated thiol group, or a part thereof which includes the glutathionylated region, and consists of at least 10 amino acid residues,

[7] An antibody specifically recognizing glutathionylation of a thiol group of a cysteine in an amino acid sequence represented by SEQ ID NO: 2, and

[8] A diagnostic agent or a diagnostic kit for a lesion resulting from vascular aging comprising an antibody specifically recognizing an apolipoprotein B100 having a glutathionylated thiol group.

Effects of the Invention

[0009] According to the present invention, since the correlation between an apolipoprotein B100 having a glutathionylated thiol group and a vascular lesion has been elucidated, an apolipoprotein B100 wherein a thiol group is modified or a part thereof can be used as a predicting factor for vascular aging. An examination method of the present invention using such a predicting factor as an index can make judgment briefly and with high accuracy that there is a lesion resulting from vascular aging or a risk for vascular aging, and is useful for diagnosis, follow-up, prognostic expectation, preclinical diagnosis, carrier diagnosis, or the like of a lesion resulting from vascular aging. Further, an antibody, and a diagnostic agent and a diagnostic kit comprising the antibody of the present invention can be used as a tool suited for the examination method of the present invention.

Brief Description of the Drawings**[0010]**

FIG. 1 is a drawing showing immunological measurement of a glutathionylated apolipoprotein B100 by SDS-slab gel electrophoresis. In (A), control serum from a healthy subject and serum from an ASO patient are used as samples, which are stained by an anti-apolipoprotein B100 antibody. Lane 1: Control serum + 5 mM DTT, Lane 2: Patient serum + 5 mM DTT, Lane 3: Control serum, Lane 4: Patient serum. In (B), control serum from a healthy subject and serum from an ASO patient are used as samples, which are stained by an anti-glutathionylated apolipoprotein B100 antibody. Lane 1: Control serum + 5 mM DTT, Lane 2: Patient serum + 5 mM DTT, Lane 3: Control serum, Lane 4: Patient serum. In (C), a glutathionylated apolipoprotein B100 produced in the control serum from a healthy subject is stained by an anti-apolipoprotein B100 antibody (upper line) and by an anti-glutathionylated apolipoprotein B100 antibody (lower line). Lane 1: 5% β -ME added, Lane 2: β -ME not added, Lane 3: 5 mM glutathione + 0.5 mM hydrogen peroxide added, Lane 4: 10 mM glutathione + 0.5 mM hydrogen peroxide added.

FIG. 2 is a drawing showing measurement of a glutathionylated apolipoprotein B100 in the serum from an ASO patient. (control (n=10) average 0.92 ± 0.43 ; I (n=6) average 2.96 ± 1.08 ; II (n=27) average 3.18 ± 1.47 ; III, IV (n=18) average 3.97 ± 1.73)

FIG. 3 is a drawing showing measurement of a glutathionylated apolipoprotein B100 in the serum from a diabetes patient. (control (n=10) average 1.07 ± 0.18 ; no DM complication (n=12) average 0.91 ± 0.41 ; DM, ASO(-) with other complication (n=52) average 2.24 ± 1.90 ; DM, ASO(+) (n=26) average 2.71 ± 1.49)

FIG. 4 is a drawing showing investigation of quantitative performance of an immune reaction using a purified glu-

tathionylated apolipoprotein B100 as the antigen and using an anti-glutathionylated apolipoprotein B100 antibody. (A) is an electrophoresis photograph showing measurement results by the western blot method. (B) is a quantification graph showing the results of (A).

FIG. 5 is a drawing showing detection of a protein in the serum from a diabetes patient isolated by the immunoprecipitation method. (A) shows an anti-glutathionylated apolipoprotein B100 antibody and (B) shows an anti-apolipoprotein B100 antibody.

FIG. 6 is a drawing showing the thiol transferase activity in the serum from an ASO patient.

Best Mode for Carrying Out the Invention

[0011] The present invention provides a novel predicting factor for vascular aging. The present invention targets a region that underwent reversible oxidative modification, rather than a modified protein that changes irreversibly by "oxidative stress" considered to particularly accelerate vascular aging. Living organisms have a high reduction power and thus protect themselves from oxidative stress. A sensor for such stress is, for example, a thiol group of a protein. Thus, the present invention takes note of the thiol group in blood protein and attempts to measure its modification.

[0012] An apolipoprotein B100 is a protein constituting a low-density lipoprotein (LDL), and in human beings, for example, it is a protein consisting of an amino acid sequence represented by SEQ ID NO: 1. Oxidative stress causes, in an apolipoprotein B100, irreversible modification to become a denatured LDL, which is taken into vascular endothelial cells or vascular macrophage by a scavenger receptor expressed on cellular surfaces of such cells, forms plaque in the blood vessel and thereby contributes to the development of an arteriosclerotic lesion. Further, oxidative stress causes diversified lesions including vascular aging. As will be described in examples shown later, a significant increase in apolipoprotein B100 having a glutathionylated thiol group was observed in the serum from a diabetes patient with a vascular lesion as compared to the protein in the serum from a diabetes patient without a vascular lesion. Therefore, an apolipoprotein B100 having a glutathionylated thiol group can be an excellent predicting factor for vascular aging.

[0013] The predicting factor of the present invention is characterized in that it comprises an apolipoprotein B100 having a glutathionylated thiol group, or a part thereof which includes the glutathionylated region, and consists of at least 10 amino acid residues. Specifically, a polypeptide containing an amino acid sequence is preferred wherein at least a thiol group in the cysteine in the amino acid sequence represented by SEQ ID NO: 2 (VPSCKLDFRE) is glutathionylated.

[0014] "Glutathionylation of a thiol group" as used herein denotes a thiol group of a cysteine of an apolipoprotein B100 in a -S-SG state reversible from an ordinary reduced form (-SH) due to oxidative stress or the like. This is different from a state that is further irreversibly modified by oxidative stress.

[0015] Vascular aging includes a physiological change of a blood vessel (artery) due to increased age, and a pathological change of a blood vessel induced by hypertension, hyperlipidemia, obesity, diabetes mellitus, smoking, cirrhosis hepatitis, auto immune disease, or the like.

[0016] Further, the present invention relates to an examination method of a lesion resulting from vascular aging characterized in that an apolipoprotein B100 having a glutathionylated thiol group is detected using a biological sample. The method of the present invention allows not only detection of a possibility of a lesion resulting from vascular aging, but also the risk of a lesion resulting from vascular aging.

[0017] In lesions resulting from vascular aging, arteriosclerotic changes such as damage of vascular endothelial cells, thrombus formation, intimal thickening, vascular blockage and plaque formation are recognized.

[0018] As disorders accompanied by lesions resulting from vascular aging, diabetes mellitus, cerebrovascular disturbance, cardiovascular disturbance, obstructive arteriosclerosis, dementia, atherosclerosis, hypertension, obesity and the like are mentioned.

[0019] Although a subject to which the examination method of the present invention can be applied is preferably a human being, mammals other than a human being may be used. For such mammals, for example, mouse, rat, rabbit, canine, feline, equine, sheep, bovine, goat, swine, miniature pig, hairless pig, simian and the like are mentioned.

[0020] A test subject of the present invention is not particularly limited, and for human beings, those undergoing general medical check-up, those having a vascular aging risk, or those with lesions resulting from vascular aging and the like may be mentioned.

[0021] "Those having a vascular aging risk" preferably denotes human beings and the like with diabetes mellitus, hypertension, hyperlipidemia, obesity, or metabolic syndrome.

[0022] A biological sample applicable to the method of the present invention is a tissue or a body fluid in which an apolipoprotein B100 can exist, and is preferably a blood sample. As for the blood, any of whole blood, serum, and plasma may be used, and these may be obtained properly by treating blood taken from a subject by an ordinary method. Although not particularly limited, a blood sample is preferably serum. An apolipoprotein B100 having a glutathionylated thiol group may exist in the form of an "LDL containing an apolipoprotein B100 having a glutathionylated thiol group (glutathionylated LDL)", as well as an apolipoprotein B100 having a glutathionylated thiol group, while any of the forms can be measured by the method of the present invention.

[0023] In the present invention, detection of an apolipoprotein B100 having a glutathionylated thiol group in the blood sample isolated from a human being, is not particularly limited, and for example, methods such as an immunochemical method may be used. Among them, detection is preferably carried out by an immunochemical method that utilizes an antibody specifically recognizing an apolipoprotein B100 having a glutathionylated thiol group. Meanwhile, "detection of an apolipoprotein B100 having a glutathionylated thiol group" as used herein denotes not only qualitative detection of more than a certain concentration of an apolipoprotein B100 having a glutathionylated thiol group, but also quantitative measurement of the concentration of an apolipoprotein B100 having a glutathionylated thiol group.

[0024] There is no limitation for the immunochemical method used for measuring the concentration of an apolipoprotein B100 having a glutathionylated thiol group in a blood sample, and a conventionally known method such as dot-blot assay, western blot method, enzyme immunoassay (ELISA), latex agglutination assay, immuno-chromatography, radioimmunoassay (RIA), fluoroimmunoassay (FIA), and turbidimetry for measurement of turbidity accompanying the formation of an antigen-antibody complex are mentioned. Of them, it is preferable to determine the concentration of an apolipoprotein B100 having a glutathionylated thiol group from the difference of color development by the western blot method or dot-blot assay, while an antigen of a known concentration is used as the control.

[0025] When an apolipoprotein B100 having a glutathionylated thiol group is detected at more than a certain level in the blood sample, the subject from whom the blood sample is derived may be judged to have a lesion resulting from vascular aging or a risk for vascular aging. In this case, the higher the concentration of an apolipoprotein B100 having a glutathionylated thiol group in the blood sample, the higher the possibility or the risk that the subject has the lesion. Further, when an apolipoprotein B100 having a glutathionylated thiol group is detected at more than a certain level in the blood sample, it may be judged that the capability for reducing a glutathionylated apolipoprotein B100 in a living organism decreased in the subject from whom the blood sample is derived. In this case, the higher the concentration of an apolipoprotein B100 having a glutathionylated thiol group in a blood sample, the higher the possibility that the reducing power is decreased. On the other hand, when an apolipoprotein B100 having a glutathionylated thiol group is detected at less than a certain level in the blood sample, it may be judged that the subject from whom the blood sample is derived has a lower possibility or risk of having a lesion resulting from vascular aging, and that the capability of reducing a glutathionylated apolipoprotein B100 in living organisms is increased or maintained.

[0026] When an apolipoprotein B100 having a glutathionylated thiol group is detected in the blood sample, and when the amount of an apolipoprotein B100 having a glutathionylated thiol group in the blood sample is greater, it can be judged that a possibility or risk for having a lesion resulting from vascular aging is higher as compared to a case where the amount is less, and the possibility that the reducing power of a glutathionylated apolipoprotein B100 decreased in the living organism is higher.

[0027] Further, the present invention provides a diagnostic agent for a lesion resulting from vascular aging comprising a substance for detecting an apolipoprotein B100 having a glutathionylated thiol group.

[0028] As for the substance, although there is no limitation as long as the substance is capable of detecting an apolipoprotein B100 having a glutathionylated thiol group in the above-mentioned method, an antibody specifically recognizing an apolipoprotein B100 having a glutathionylated thiol group (hereafter, referred to as the "antibody of the present invention") is preferable.

[0029] The "antibody" in the present invention includes natural antibodies such as a polyclonal antibody and a monoclonal antibody (mAb), chimeric antibodies that can be produced using a genetic recombination technology, humanized antibodies and single-chain antibodies, human antibodies that can be produced using a human antibody producing transgenic animal or the like, antibody fragments produced by Fab expression library, and binding fragments thereof, but is not limited thereto.

[0030] The antibody of the present invention included in the diagnostic agent may be either a polyclonal antibody or a monoclonal antibody as long as it specifically binds to an apolipoprotein B100 wherein a thiol group derived from a mammal, preferably from a human being, is glutathionylated.

[0031] The binding fragment denotes a region of a part of the above-mentioned antibody, and specifically, for example, F(ab')₂, Fab', Fab, Fv (variable fragment of antibody), sFv, dsFv (disulphide stabilized Fv), dAb (single domain antibody) and the like are mentioned (Exp. Opin. Ther. Patents, Vol. 6, No. 5, p. 441-456, 1996).

[0032] The class of the antibody is not particularly limited and includes antibodies having any isotype such as IgG, IgM, IgA, IgD, IgE and the like. Preferably, IgG and IgM are mentioned, while IgG is more preferable when ease of purification and the like is taken into consideration.

[0033] A polyclonal antibody or a monoclonal antibody can be manufactured by an existing ordinary manufacturing method. That is, for example, an immunogen is given together with the Freund's Adjuvant as necessary to a mammal, e.g., mouse, rat, hamster, guinea pig, rabbit, feline, canine, swine, goat, equine or bovine, preferably mouse, rat, hamster, guinea pig, goat, equine or rabbit (in the case of polyclonal antibody) for immunization, and the same is given to mouse, rat or hamster (in the case of monoclonal antibody).

[0034] The immunogen is used cross-linked to a carrier, as necessary. For carriers, for example, BSA, KLH, and the like are mentioned. Further, a protein derived from animals to be immunized (e.g., a serum protein and the like) may be

used as the carrier.

[0035] As for the immunogen used for production of an antibody of the present invention, an amino acid sequence represented by SEQ ID NO: 1 or a polypeptide having a partial sequence thereof is used. Preferably, the polypeptide comprises an amino acid sequence in which the thiol group of the cysteine in SEQ ID NO: 2 (VPCKLDFRE) is glutathionylated or a partial sequence thereof. Specifically, the immunogen to be used for production of the antibody of the present invention is a peptide consisting of an amino acid sequence represented by SEQ ID NO: 2 (VPCKLDFRE) or a partial sequence thereof. Although the length of the partial sequence is not limited as long as it possesses immunogenicity as an epitope, the length is preferably not less than 6 amino acids, more preferably not less than 8 amino acids, further preferably 10 amino acids.

[0036] For the sake of cross-linking the above-mentioned peptide to a carrier, one or a plurality of amino acids may be added. Although the number of amino acids to be added is not particularly limited, in consideration of the specificity of the antibody to be produced, the number of amino acids is preferably 1 to 10, more preferably 1 to 5, further preferably 1 to 2, most preferably 1.

[0037] Although the position of the amino acid to be added may be either an N-terminal or a C-terminal of the polypeptide, the amino acid is preferably added to an N-terminal.

Although the type of the amino acid to be added may be any of 20 types of amino acids known per se, preferably, at least one cysteine is included in the amino acid to be added. More preferably, the amino acid to be added consists of a cysteine.

[0038] Specifically, the polyclonal antibody can be produced as follows: that is, an immunogen is injected one to several times to a mouse, a rat, a hamster, a guinea pig, a goat, a horse or a rabbit, preferably a goat, a horse or a rabbit, more preferably a rabbit through subcutaneous, intramuscular, intravenous, foot pad, or intraperitoneal routes, and the mammal is sensitized. Normally, immunization is performed once to five times approximately every 1 to 14 days after the first immunization, and serum is obtained from the mammal that is sensitized about 1 to 5 days after the final immunization.

[0039] While the serum may be used as the polyclonal antibody, preferably, the antibody is isolated and/or purified by saturated ammonium sulfate, an euglobulin sedimentation method, a caproic acid method, a caprylic acid method, ion-exchange chromatography (DEAE or DE52, etc.), anti-immunoglobulin column or protein A/G column, or affinity column chromatography using a column or the like in which an immunogen is cross-linked.

[0040] A monoclonal antibody is produced by preparing a hybridoma (fused cell) from the antibody-producing cell obtained from the above-mentioned sensitized animal and a myeloma cell without auto-antibody producibility (myeloma cell), cloning the hybridoma, and selecting a clone that produces a monoclonal antibody exhibiting specific affinity to the immunogen used for immunization of the mammal.

[0041] Specifically, the monoclonal antibody can be produced as follows: that is, a mouse, a rat or a hamster (including transgenic animals created so as to produce an antibody derived from other animals such as a human antibody producing transgenic mouse) is sensitized by one to several times of injections of the immunogen through subcutaneous, intramuscular, intravenous, foot pad, or intraperitoneal routes or by grafting the same. Normally, immunization is performed once to four times approximately every 1 to 14 days after the first immunization, and antibody-producing cells are obtained from the mammal that is sensitized about 1 to 5 days after the final immunization.

[0042] Preparation of a hybridoma (fused cell) that secretes a monoclonal antibody can be performed according to the method proposed by Kohler and Millstein (Nature, Vol. 256, p. 495-497, 1975) and a modification method conforming to the method. In other words, antibody-producing cells contained in the spleen, lymph node, bone marrow or tonsilla, or the like obtained from the sensitized mammal as mentioned above, preferably antibody-producing cells contained in the spleen, and myeloma cells without auto-antibody producibility derived from preferably a mammal such as a mouse, a rat, a guinea pig, a hamster, a rabbit or a human being, more preferably from a mouse, a rat or a human being, are subject to cell fusion to prepare such a hybridoma.

[0043] For myeloma cells used for cell fusion, for example, myeloma P3/X63-AG8. 653 (653; ATCC No. CRL1580), P3/NSI/1-Ag4-1(NS-1), P3/X63-Ag8.U1(P3U1), SP2/0-Ag14(Sp2/0, Sp2), PAI, F0 or BW5147, derived from a mouse, myeloma 210RCY3-Ag. 2. 3. derived from a rat, or myeloma U-266AR1, GM1500-6TG-A1-2, UC729-6, CEM-AGR, D1R11 or CEM-T15, derived from a human being, may be used.

[0044] Screening of hybridoma clones producing a monoclonal antibody can be performed by culturing hybridoma in, for example, a microtiter plate, and measuring the reactivity of the culture supernatant of the well where proliferation is observed, against the immunogen used in the above-mentioned sensitization by enzyme immunoassay, for example, RIA or ELISA and the like.

[0045] Production of a monoclonal antibody from the hybridoma can be performed by culturing the hybridoma in vitro, or in vivo in a mouse, a rat, a guinea pig, a hamster or a rabbit or the like, preferably a mouse or a rat, more preferably in vivo in peritoneal effusion and the like of a mouse, and isolating the antibody from the culture supernatant or peritoneal effusion of the mammal thus obtained.

[0046] When culturing is performed in vitro, the hybridoma is proliferated, maintained and stored to meet with various

conditions such as characteristics of the cell species to be cultured, the purpose of the test and research, and the culture method, and a known culture medium such as those used for production of a monoclonal antibody in the culture supernatant or any culture medium induced and prepared from a known basal medium can be used.

[0047] The monoclonal antibody is preferably isolated and/or purified similarly as the above-mentioned polyclonal antibody.

[0048] A chimeric antibody can be produced by reference to, for example, "Experimental Medicine (Extra edition), Vol. 6, No. 10, 1988", JP-B-H03-73280, a humanized antibody can be produced by reference to, for example, JP-T-H04-506458, JP-A-62-296890, and a human antibody can be produced by reference to, for example, Nature Genetics, Vol. 15, p. 146-156, 1997, Nature Genetics, Vol. 7, p. 13-21, 1994, JP-T-H04-504365, WO94/25585, "Nikkei Science, June, pp 40-50, 1995", Nature, Vol. 368, p. 856-859, 1994, JP-T-H06-500233, respectively.

F(ab')₂ and Fab' can be produced by treating immunoglobulin with pepsin and papain, respectively, which are proteolytic enzymes.

[0049] The antibody of the present invention produced by the above-mentioned method is able to recognize a human apolipoprotein B100 having a glutathionylated thiol group with extremely high sensitivity and specificity and is therefore very useful for detection and quantitative determination of an apolipoprotein B100 having a glutathionylated thiol group in a biological sample derived from a human.

[0050] The antibody of the present invention is included in the diagnostic agent in a free state, a labeled state, or a solid-phased state.

[0051] Use of the diagnostic agent of the present invention allows diagnosis of lesions resulting from vascular aging by the above-mentioned methods.

[0052] The diagnostic agent of the present invention can also be used as a diagnostic kit of lesions resulting from vascular aging which further comprises a reagent or the like used in the above-mentioned detection method. For the reagent or the like, specifically, a buffer solution for dilution of reagents and biological samples, a fluorescence dye, a reaction vessel, a positive control, a negative control, an instruction manual describing the inspection protocol and the like are mentioned. These elements may be mixed in advance as necessary. Use of the kit allows simple diagnosis of lesions resulting from vascular aging according to the present invention.

[0053] Contents of all publications including patent specifications cited herein are incorporated herein by reference in their entirety as if they had each been set forth in full.

[0054] Although the present invention will be described hereafter in detail referring to examples, the present invention is not limited to the following examples. In the examples shown hereafter an "apolipoprotein B100 having a glutathionylated thiol group" will be abbreviated as a "glutathionylated apolipoprotein B100".

Examples

[0055] Apolipoprotein B100 protein C-terminal 10 amino acid residues (VPCKLDFRE: SEQ ID NO.: 2) containing a reactive thiol group were synthesized (SIGMA). Glutathione (100 mM) was added to the synthesized peptide solution, which was then incubated at 37°C for 15 minutes in the presence of hydrogen peroxide (0.5 mM) for glutathionylation of the thiol group. The glutathionylation disappeared by reduction by treatment with a reducing agent and therefore, it was confirmed that the thiol group was in the state of becoming reversible -S-SG (glutathionylated). A specific antibody against a peptide having a glutathionylated thiol group was produced in a house rabbit (see Susanne Mohr et al., The Journal of Biological Chemistry, vol. 274(14), p. 9427-9430 (1999), Hjelle O. P. et al., Eur. J. Neurosci., vol. 6(5), p. 793-804 (1994) and Cheng G et al., Archives of Biochemistry and Biophysics, vol. 435, p. 42-49 (2005)).

"Quantitative determination of glutathionylated apolipoprotein B100 in serum"

[0056] SDS-slab gel electrophoresis was performed in the absence of a reducing agent such as beta-mercaptoethanol (β-ME) or DTT (dithiothreitol) using human serum as a sample. It was stained with an anti-glutathionylated apolipoprotein B100 antibody and an anti-apolipoprotein B100 antibody using the western blot method and the degree of glutathionylation of the thiol group was determined.

Results of experiments

1. Immunological measurement by SDS-slab gel electrophoresis (FIG. 1)

[0057]

(A) Control serum from a healthy subject and serum from a patient with obstructive arteriosclerosis (ASO) were used as samples and stained with an anti-apolipoprotein B100 antibody (provided by SRL Ltd.). Bands corresponding

to an apolipoprotein B100 were recognized only in the absence of DTT (lanes 3 and 4). The degree of staining was slight in the healthy control (lane 3) and was strong in the sample from an ASO patient (lane 4).

(B) The same samples were stained with an anti-glutathionylated apolipoprotein B100 antibody. They were stained with an anti-glutathionylated apolipoprotein B100 antibody in the absence of DTT. Although glutathionylation of the thiol group was observed with the fragmented apolipoprotein B100 fraction of an ASO patient serum, glutathionylation occurred also in a normal size apolipoprotein B100 that was not fragmented (lane 4). Meanwhile, it is known that an apolipoprotein B100 is fragmented during the course of oxidative denaturation due to oxidative stress and that lipid peroxides also increase (Cushing SD et al., Proc. Natl. Acad. Sci. USA, vol. 87, p. 5134-5138 (1990)).

(C) Preparation of glutathionylated apolipoprotein B100 using control serum from healthy subject

Hydrogen peroxide (0.5 mM) and glutathione (5 mM, 10 mM) were added to the control serum in the absence of β -ME, and reacted at 37°C for 24 hours. Then, presence of a glutathionylated apolipoprotein B100 that was not identified in the control was observed (lanes 3 and 4). The result thus obtained indicates that the thiol group of an apolipoprotein B100 is glutathionylated by oxidative stress.

2. Measurement of glutathionylated apolipoprotein B100 in serum from ASO patient (FIG. 2)

[0058] Glutathionylated apolipoprotein B100 was measured using serum from an ASO patient as a sample and a significant increase in glutathionylated apolipoprotein B100 was observed with serum from an ASO patient as compared to the control serum from a healthy subject ($p < 0.001$). Pathological conditions of an ASO patient were investigated according to the Fontain classification, which revealed that there was no significant correlation, although an upward tendency of a glutathionylated apolipoprotein B100 was observed with the progress of the disease condition.

The results thus obtained suggest that determination of the concentration of a glutathionylated apolipoprotein B100 in the serum using the antibody of the present invention allows discrimination between healthy people and early-stage ASO patients.

3. Investigation of diabetic patients (FIG. 3)

[0059] Glutathionylated apolipoprotein B100 in diabetic patients (DM) was investigated with regard to presence or absence of a vascular lesion. A significantly correlative increase in glutathionylated apolipoprotein B100 was observed with the serum from diabetic patients with a vascular lesion or highly liable to have the same in the future as compared to the serum from diabetic patients without a vascular lesion or less liable to have the same in the future (Table 1).

[0060]

Table 1
Significant difference (t-test)

	DM (no complication)	DM, ASO(-) (with other complication)	DM, ASO(+)
control	0.467	0.0000208*	0.00000441*
DM (no complication)		0.0000227*	0.00000271*
DM, ASO(-) (with other complication)			0.239

(Numerical value shows probability of no significant difference. *; $p < 0.05$)

4. Quantitative performance of anti-glutathionylated apolipoprotein B100 antibody and antigen (purified glutathionylated apolipoprotein B100) in immune reaction (FIG. 4)

(A) Quantitative determination of purified glutathionylated apolipoprotein B100 by western blot method using anti-glutathionylated apolipoprotein B100 antibody

[0061] A glutathionylated apolipoprotein B100 (GSH-apoB100) equivalent to 10 ng to 90 ng was subjected to electrophoresis and was assayed by the western blot method. An anti-glutathionylated apolipoprotein B100 antibody was diluted 5000-fold to be used as the antibody and was reacted at room temperature for 1 hour. Intensive bands were observed at locations corresponding to glutathionylated apolipoprotein B100 fractions.

(B) Analysis of data of (A)

[0062] The results of (A) were quantified to obtain a calibration curve. As a result, a calibration curve showing antigen-level-dependent linearity was obtained.

5. Extraction of protein that reacts with anti-apolipoprotein B100 antibody from patient serum using immunoprecipitation method and confirmation of effects by causing anti-glutathionylated apolipoprotein B100 antibody to act thereon (FIG. 5)

[0063] The serum from patients and an anti-apolipoprotein B100 antibody (SRL Ltd.) were caused to react and a protein that reacts with an anti-apolipoprotein B100 antibody was separated and extracted using an immunoprecipitation method using protein A sepharose. Following this, each of original serum (untreated), a protein not reacted with an anti-apolipoprotein B100 antibody (not adsorbed by column), and a protein bound to an anti-apolipoprotein B100 antibody (adsorbed by column) was subjected to electrophoresis, and an anti-glutathionylated apolipoprotein B100 antibody (FIG. 5 (A)) and an anti-apolipoprotein B100 antibody (FIG. 5 (B)) were caused to act. The protein immunoprecipitated by an anti-apolipoprotein B100 antibody was detected around 175 kDa for both anti-glutathionylated apolipoprotein B100 antibody and anti-apolipoprotein B100 antibody, which were approximately correspondent to each other. This finding revealed that a band detected by an anti-apolipoprotein B100 antibody is specifically detected by an anti-glutathionylated apolipoprotein B100 antibody.

[0064] From the results thus obtained, it has been found that the measurement method using the antibody of the present invention has excellent sensitivity and specificity as compared to the conventional methods. If a measurement method as a stress sensor is established, extensive clinical applications as a novel vascular aging marker would become possible.

6. Provision of predicting factor for vascular aging and of examination method of early-stage lesion resulting from vascular aging

[0065] The meaning of measurement of a glutathionylated apolipoprotein B100 as a risk factor for obstructive arteriosclerosis was investigated.

Using serum from 41 patients with obstructive arteriosclerosis and from 38 controls, a glutathionylated apolipoprotein B100 was measured and investigated by a Yates continuity-corrected χ^2 test (Table 2).

It is apparent that a glutathionylated apolipoprotein B100 is an assessment factor having both extremely high sensitivity and specificity as compared to hs-CRP value that is already known to elevate in this disorder, and soluble LOX-1 (sLOX-1) value that is appreciated as an early diagnosis marker for vascular endothelial cell disorders such as cardiac infarction.

[0066]

Table 2

Sensitivity and specificity of sLOX-1, hs-CRP, and S-glutathionylated protein for ASO patients

	sLOX-1	hs-CRP	S-glutathionylated protein
Control (n=38)			
Positive, n	21	13	4
Specificity ASO (n=41)	45	66	89
Positive, n	31	18	28
χ^2	2.78	0.42	24.96
<i>P</i>	0.095	0.515	<0.0001
Sensitivity	76	44	68

Cut-off levels are 100 pg/ml for sLOX-1, 4 μ l/ml for hs-GRP, and 2.5 relative intensity for thiol-modification. χ^2 was determined by a Yates continuity-corrected χ^2 test, and the probability value was obtained from comparison with non-ASO patients.

5 7. Meaning as index for decrease of blood redox ability which is the basis of vascular aging

[0067] Investigation was made as to what a glutathionylated apolipoprotein B100 reflects in a living organism.

[0068] In the serum, vitamins which are antioxidative substances, glutathione, glutathione peroxidase, thioredoxin and glutaredoxin (GRX), which are redox proteins, and the like are present. Although these substances are considered to execute indirectly reduction of a glutathionylated serum protein, they do not directly reduce glutathionylated serum protein. The present inventors focused attention on GRX that has a direct reduction action on a cysteine group oxidatively modified in a glutathionylated protein, and have developed a method for measuring the activity of GRX dependent thiol transferase in the serum using low molecular weight protein tyrosine phosphatase (LMW-PTP) (Kanda, M, Kondo, T. et al., J. Biol. Chem., vol. 281(39), p. 28518-28528, 2006) which is a tyrosine phosphatase discovered by the present inventors to be a substrate of GRX. Specifically, LMW-PTP (100 μ l/50 μ g (2.8 nmols)) and 35 S-GSH (5 μ l (2 pmoles, 50 nmols DTT)) were mixed and placed on ice for 5 minutes, then GSSG (28 nmols) and H₂O₂ (100 nmols) (total amount 150 μ l) were added thereto and the mixture was left standing at 4°C for 24 hours and filtrated by spin column to yield 35 S-GS-LM-PTP (PTP labeled). 35 S-GS-LM-PTP (5 μ l) thus obtained and serum (0.5 μ l) were mixed, 0.2 M NaH₂PO₄ (1 μ l) (adjust pH to 7.0) and 7.5 mM GSH or PBS (-) (1 μ l) were added thereto and left at 37°C for 30 minutes, a 2 \times laemmli's solution (7.5 μ l) was added to obtain a measurement mixture, and were subjected to the measurement of radioactivity released from a cysteine group of radiolabeled glutathionylated LMW-PTP. As a result, all patients with obstructive arteriosclerosis showed reduced activity of GRX dependent thiol transferase in the blood as compared to that of the control (FIG. 6). This suggests that the reduction power decreases in the patient serum, a protein SH group is in a state easily modified with oxidative stress, and that a power for reducing those oxidatively modified (glutathionylated) is low.

8. Prediction of vascular lesion progression unrecognizable by other measurement methods

Assessment of glutathionylated apolipoprotein B100 as vascular lesion predicting factor

[0069] Although definite diagnosis of obstructive arteriosclerosis by angiography after progression of the lesion has been developed, prediction of an early stage of onset and incipient stage is not at all sufficient. An ABI inspection is objectively assessed at an early stage. In patients with obstructive arteriosclerosis, an extremely high positive correlation is observed between the ABI level and the glutathionylated apolipoprotein B100 level. Further, determination of the glutathionylated apolipoprotein B100 level of serum from patients with diabetes mellitus, which is one of the incipient disorders of this disease, revealed elevation of the glutathionylated apolipoprotein B100 level even with those who did not show any apparent symptom or change in the ABI level. They are considered to be in incipient stage and require careful follow-up in the future (data not shown). Meanwhile, though in one case, the glutathionylated apolipoprotein B100 level of a diabetic patient who complained of intermittent pain in the lower legs was measured and found to be normal. In this case, the patient had a complication of marked hypertension, obesity, and hyperlipidemia, and was strongly suspected of suffering obstructive arteriosclerosis. However, since the ABI level was also normal, the possibility of other disorder was strongly suggested. From this incident, it is expected that a more accurate diagnosis will be enabled by determination of the glutathionylated apolipoprotein B100 level in addition to the sole determination of ABI.

45 **Industrial Applicability**

[0070] It is considered that a method of determining, as a stress sensor, a serum apolipoprotein B100 protein having a glutathionylated thiol group can be extensively used in clinical applications as a novel vascular aging marker. Metabolic syndrome patients constantly increasing in number year by year may encounter serious lifestyle-related diseases, which include cerebral infarction, cardiac infarction, obstructive arteriosclerosis and the like due to vascular aging. In addition, a vascular lesion underlies a complication of diabetes mellitus such as blindness and impairment of renal function. Factors for predicting onset of these disorders have not been established so far. It is expected that the method of determining a vascular aging marker established by the present invention would make great contribution to determination of prognosis of metabolic syndrome patients as well as diabetic patients. Further, development of a screening system for anti-arteriosclerotic agents using this probe is also possible. It is also expected that the determination method of the present invention would be applicable to objective diagnosis and judgment of therapeutic effects of dementia which is supposed to become a serious social problem in the future.

This application is based on a patent application No. 2005-344630 filed in Japan (filing date: November 29, 2005), the

EP 1 956 029 A1

contents of which are incorporated in full herein by this reference.

5

10

15

20

25

30

35

40

45

50

55

EP 1 956 029 A1

SEQUENCE LISTING

<110> NAGASAKI UNIVERSITY
 5 <120> VASCULAR AGING-PREDICTING FACTOR AND UTILIZATION OF THE SAME
 <130> 091000
 <150> JP2005-344630
 <151> 2005-11-29
 10 <160> 2
 <170> PatentIn version 3.2

 <210> 1
 <211> 4536
 <212> PRT
 <213> Homo sapiens
 <400> 1
 Glu Glu Glu Met Leu Glu Asn Val Ser Leu Val Cys Pro Lys Asp Ala
 1 5 10 15
 Thr Arg Phe Lys His Leu Arg Lys Tyr Thr Tyr Asn Tyr Glu Ala Glu
 20 25 30
 Ser Ser Ser Gly Val Pro Gly Thr Ala Asp Ser Arg Ser Ala Thr Arg
 35 40 45
 25 Ile Asn Cys Lys Val Glu Leu Glu Val Pro Gln Leu Cys Ser Phe Ile
 50 55 60
 Leu Lys Thr Ser Gln Cys Thr Leu Lys Glu Val Tyr Gly Phe Asn Pro
 65 70 75 80
 30 Glu Gly Lys Ala Leu Leu Lys Lys Thr Lys Asn Ser Glu Glu Phe Ala
 85 90 95
 Ala Ala Met Ser Arg Tyr Glu Leu Lys Leu Ala Ile Pro Glu Gly Lys
 100 105 110
 Gln Val Phe Leu Tyr Pro Glu Lys Asp Glu Pro Thr Tyr Ile Leu Asn
 115 120 125
 35 Ile Lys Arg Gly Ile Ile Ser Ala Leu Leu Val Pro Pro Glu Thr Glu
 130 135 140
 Glu Ala Lys Gln Val Leu Phe Leu Asp Thr Val Tyr Gly Asn Cys Ser
 145 150 155 160
 40 Thr His Phe Thr Val Lys Thr Arg Lys Gly Asn Val Ala Thr Glu Ile
 165 170 175
 Ser Thr Glu Arg Asp Leu Gly Gln Cys Asp Arg Phe Lys Pro Ile Arg
 180 185 190
 45 Thr Gly Ile Ser Pro Leu Ala Leu Ile Lys Gly Met Thr Arg Pro Leu
 195 200 205
 Ser Thr Leu Ile Ser Ser Ser Gln Ser Cys Gln Tyr Thr Leu Asp Ala
 210 215 220
 Lys Arg Lys His Val Ala Glu Ala Ile Cys Lys Glu Gln His Leu Phe
 225 230 235 240
 50 Leu Pro Phe Ser Tyr Asn Asn Lys Tyr Gly Met Val Ala Gln Val Thr
 245 250 255
 Gln Thr Leu Lys Leu Glu Asp Thr Pro Lys Ile Asn Ser Arg Phe Phe
 260 265 270
 55 Gly Glu Gly Thr Lys Lys Met Gly Leu Ala Phe Glu Ser Thr Lys Ser
 275 280 285

EP 1 956 029 A1

Thr Ser Pro Pro Lys Gln Ala Glu Ala Val Leu Lys Thr Leu Gln Glu
 290 295 300
 5 Leu Lys Lys Leu Thr Ile Ser Glu Gln Asn Ile Gln Arg Ala Asn Leu
 305 310 315 320
 Phe Asn Lys Leu Val Thr Glu Leu Arg Gly Leu Ser Asp Glu Ala Val
 325 330 335
 10 Thr Ser Leu Leu Pro Gln Leu Ile Glu Val Ser Ser Pro Ile Thr Leu
 340 345 350
 Gln Ala Leu Val Gln Cys Gly Gln Pro Gln Cys Ser Thr His Ile Leu
 355 360 365
 15 Gln Trp Leu Lys Arg Val His Ala Asn Pro Leu Leu Ile Asp Val Val
 370 375 380
 Thr Tyr Leu Val Ala Leu Ile Pro Glu Pro Ser Ala Gln Gln Leu Arg
 385 390 395 400
 20 Glu Ile Phe Asn Met Ala Arg Asp Gln Arg Ser Arg Ala Thr Leu Tyr
 405 410 415
 Ala Leu Ser His Ala Val Asn Asn Tyr His Lys Thr Asn Pro Thr Gly
 420 425 430
 Thr Gln Glu Leu Leu Asp Ile Ala Asn Tyr Leu Met Glu Gln Ile Gln
 435 440 445
 25 Asp Asp Cys Thr Gly Asp Glu Asp Tyr Thr Tyr Leu Ile Leu Arg Val
 450 455 460
 Ile Gly Asn Met Gly Gln Thr Met Glu Gln Leu Thr Pro Glu Leu Lys
 465 470 475 480
 30 Ser Ser Ile Leu Lys Cys Val Gln Ser Thr Lys Pro Ser Leu Met Ile
 485 490 495
 Gln Lys Ala Ala Ile Gln Ala Leu Arg Lys Met Glu Pro Lys Asp Lys
 500 505 510
 35 Asp Gln Glu Val Leu Leu Gln Thr Phe Leu Asp Asp Ala Ser Pro Gly
 515 520 525
 Asp Lys Arg Leu Ala Ala Tyr Leu Met Leu Met Arg Ser Pro Ser Gln
 530 535 540
 40 Ala Asp Ile Asn Lys Ile Val Gln Ile Leu Pro Trp Glu Gln Asn Glu
 545 550 555 560
 Gln Val Lys Asn Phe Val Ala Ser His Ile Ala Asn Ile Leu Asn Ser
 565 570 575
 Glu Glu Leu Asp Ile Gln Asp Leu Lys Lys Leu Val Lys Glu Ala Leu
 580 585 590
 45 Lys Glu Ser Gln Leu Pro Thr Val Met Asp Phe Arg Lys Phe Ser Arg
 595 600 605
 Asn Tyr Gln Leu Tyr Lys Ser Val Ser Leu Pro Ser Leu Asp Pro Ala
 610 615 620
 50 Ser Ala Lys Ile Glu Gly Asn Leu Ile Phe Asp Pro Asn Asn Tyr Leu
 625 630 635 640
 Pro Lys Glu Ser Met Leu Lys Thr Thr Leu Thr Ala Phe Gly Phe Ala
 645 650 655
 Ser Ala Asp Leu Ile Glu Ile Gly Leu Glu Gly Lys Gly Phe Glu Pro
 660 665 670
 55 Thr Leu Glu Ala Leu Phe Gly Lys Gln Gly Phe Phe Pro Asp Ser Val
 675 680 685

EP 1 956 029 A1

Asn Lys Ala Leu Tyr Trp Val Asn Gly Gln Val Pro Asp Gly Val Ser
 690 695 700
 Lys Val Leu Val Asp His Phe Gly Tyr Thr Lys Asp Asp Lys His Glu
 705 710 715
 5 Gln Asp Met Val Asn Gly Ile Met Leu Ser Val Glu Lys Leu Ile Lys
 725 730 735
 Asp Leu Lys Ser Lys Glu Val Pro Glu Ala Arg Ala Tyr Leu Arg Ile
 740 745 750
 10 Leu Gly Glu Glu Leu Gly Phe Ala Ser Leu His Asp Leu Gln Leu Leu
 755 760 765
 Gly Lys Leu Leu Leu Met Gly Ala Arg Thr Leu Gln Gly Ile Pro Gln
 770 775 780
 15 Met Ile Gly Glu Val Ile Arg Lys Gly Ser Lys Asn Asp Phe Phe Leu
 785 790 795 800
 His Tyr Ile Phe Met Glu Asn Ala Phe Glu Leu Pro Thr Gly Ala Gly
 805 810 815
 20 Leu Gln Leu Gln Ile Ser Ser Ser Gly Val Ile Ala Pro Gly Ala Lys
 820 825 830
 Ala Gly Val Lys Leu Glu Val Ala Asn Met Gln Ala Glu Leu Val Ala
 835 840 845
 Lys Pro Ser Val Ser Val Glu Phe Val Thr Asn Met Gly Ile Ile Ile
 850 855 860
 25 Pro Asp Phe Ala Arg Ser Gly Val Gln Met Asn Thr Asn Phe Phe His
 865 870 875 880
 Glu Ser Gly Leu Glu Ala His Val Ala Leu Lys Ala Gly Lys Leu Lys
 885 890 895
 30 Phe Ile Ile Pro Ser Pro Lys Arg Pro Val Lys Leu Leu Ser Gly Gly
 900 905 910
 Asn Thr Leu His Leu Val Ser Thr Thr Lys Thr Glu Val Ile Pro Pro
 915 920 925
 35 Leu Ile Glu Asn Arg Gln Ser Trp Ser Val Cys Lys Gln Val Phe Pro
 930 935 940
 Gly Leu Asn Tyr Cys Thr Ser Gly Ala Tyr Ser Asn Ala Ser Ser Thr
 945 950 955 960
 40 Asp Ser Ala Ser Tyr Tyr Pro Leu Thr Gly Asp Thr Arg Leu Glu Leu
 965 970 975
 Glu Leu Arg Pro Thr Gly Glu Ile Glu Gln Tyr Ser Val Ser Ala Thr
 980 985 990
 Tyr Glu Leu Gln Arg Glu Asp Arg Ala Leu Val Asp Thr Leu Lys Phe
 995 1000 1005
 45 Val Thr Gln Ala Glu Gly Ala Lys Gln Thr Glu Ala Thr Met Thr
 1010 1015 1020
 Phe Lys Tyr Asn Arg Gln Ser Met Thr Leu Ser Ser Glu Val Gln
 1025 1030 1035
 50 Ile Pro Asp Phe Asp Val Asp Leu Gly Thr Ile Leu Arg Val Asn
 1040 1045 1050
 Asp Glu Ser Thr Glu Gly Lys Thr Ser Tyr Arg Leu Thr Leu Asp
 1055 1060 1065
 55 Ile Gln Asn Lys Lys Ile Thr Glu Val Ala Leu Met Gly His Leu
 1070 1075 1080
 Ser Cys Asp Thr Lys Glu Glu Arg Lys Ile Lys Gly Val Ile Ser

EP 1 956 029 A1

	1085					1090					1095				
	Ile	Pro	Arg	Leu	Gln	Ala	Glu	Ala	Arg	Ser	Glu	Ile	Leu	Ala	His
	1100						1105					1110			
5	Trp	Ser	Pro	Ala	Lys	Leu	Leu	Leu	Gln	Met	Asp	Ser	Ser	Ala	Thr
	1115						1120					1125			
	Ala	Tyr	Gly	Ser	Thr	Val	Ser	Lys	Arg	Val	Ala	Trp	His	Tyr	Asp
	1130						1135					1140			
10	Glu	Glu	Lys	Ile	Glu	Phe	Glu	Trp	Asn	Thr	Gly	Thr	Asn	Val	Asp
	1145						1150					1155			
	Thr	Lys	Lys	Met	Thr	Ser	Asn	Phe	Pro	Val	Asp	Leu	Ser	Asp	Tyr
	1160						1165					1170			
15	Pro	Lys	Ser	Leu	His	Met	Tyr	Ala	Asn	Arg	Leu	Leu	Asp	His	Arg
	1175						1180					1185			
	Val	Pro	Glu	Thr	Asp	Met	Thr	Phe	Arg	His	Val	Gly	Ser	Lys	Leu
	1190						1195					1200			
20	Ile	Val	Ala	Met	Ser	Ser	Trp	Leu	Gln	Lys	Ala	Ser	Gly	Ser	Leu
	1205						1210					1215			
	Pro	Tyr	Thr	Gln	Thr	Leu	Gln	Asp	His	Leu	Asn	Ser	Leu	Lys	Glu
	1220						1225					1230			
	Phe	Asn	Leu	Gln	Asn	Met	Gly	Leu	Pro	Asp	Phe	His	Ile	Pro	Glu
	1235						1240					1245			
25	Asn	Leu	Phe	Leu	Lys	Ser	Asp	Gly	Arg	Val	Lys	Tyr	Thr	Leu	Asn
	1250						1255					1260			
	Lys	Asn	Ser	Leu	Lys	Ile	Glu	Ile	Pro	Leu	Pro	Phe	Gly	Gly	Lys
	1265						1270					1275			
30	Ser	Ser	Arg	Asp	Leu	Lys	Met	Leu	Glu	Thr	Val	Arg	Thr	Pro	Ala
	1280						1285					1290			
	Leu	His	Phe	Lys	Ser	Val	Gly	Phe	His	Leu	Pro	Ser	Arg	Glu	Phe
	1295						1300					1305			
35	Gln	Val	Pro	Thr	Phe	Thr	Ile	Pro	Lys	Leu	Tyr	Gln	Leu	Gln	Val
	1310						1315					1320			
	Pro	Leu	Leu	Gly	Val	Leu	Asp	Leu	Ser	Thr	Asn	Val	Tyr	Ser	Asn
	1325						1330					1335			
40	Leu	Tyr	Asn	Trp	Ser	Ala	Ser	Tyr	Ser	Gly	Gly	Asn	Thr	Ser	Thr
	1340						1345					1350			
	Asp	His	Phe	Ser	Leu	Arg	Ala	Arg	Tyr	His	Met	Lys	Ala	Asp	Ser
	1355						1360					1365			
45	Val	Val	Asp	Leu	Leu	Ser	Tyr	Asn	Val	Gln	Gly	Ser	Gly	Glu	Thr
	1370						1375					1380			
	Thr	Tyr	Asp	His	Lys	Asn	Thr	Phe	Thr	Leu	Ser	Cys	Asp	Gly	Ser
	1385						1390					1395			
50	Leu	Arg	His	Lys	Phe	Leu	Asp	Ser	Asn	Ile	Lys	Phe	Ser	His	Val
	1400						1405					1410			
	Glu	Lys	Leu	Gly	Asn	Asn	Pro	Val	Ser	Lys	Gly	Leu	Leu	Ile	Phe
	1415						1420					1425			
55	Asp	Ala	Ser	Ser	Ser	Trp	Gly	Pro	Gln	Met	Ser	Ala	Ser	Val	His
	1430						1435					1440			
	Leu	Asp	Ser	Lys	Lys	Lys	Gln	His	Leu	Phe	Val	Lys	Glu	Val	Lys
	1445						1450					1455			
	Ile	Asp	Gly	Gln	Phe	Arg	Val	Ser	Ser	Phe	Tyr	Ala	Lys	Gly	Thr
	1460						1465					1470			

EP 1 956 029 A1

Tyr Gly Leu Ser Cys Gln Arg Asp Pro Asn Thr Gly Arg Leu Asn
 1475 1480 1485
 Gly Glu Ser Asn Leu Arg Phe Asn Ser Ser Tyr Leu Gln Gly Thr
 5 1490 1500
 Asn Gln Ile Thr Gly Arg Tyr Glu Asp Gly Thr Leu Ser Leu Thr
 1505 1510 1515
 Ser Thr Ser Asp Leu Gln Ser Gly Ile Ile Lys Asn Thr Ala Ser
 10 1520 1525 1530
 Leu Lys Tyr Glu Asn Tyr Glu Leu Thr Leu Lys Ser Asp Thr Asn
 1535 1540 1545
 Gly Lys Tyr Lys Asn Phe Ala Thr Ser Asn Lys Met Asp Met Thr
 1550 1555 1560
 Phe Ser Lys Gln Asn Ala Leu Leu Arg Ser Glu Tyr Gln Ala Asp
 15 1565 1570 1575
 Tyr Glu Ser Leu Arg Phe Phe Ser Leu Leu Ser Gly Ser Leu Asn
 1580 1585 1590
 Ser His Gly Leu Glu Leu Asn Ala Asp Ile Leu Gly Thr Asp Lys
 20 1595 1600 1605
 Ile Asn Ser Gly Ala His Lys Ala Thr Leu Arg Ile Gly Gln Asp
 1610 1615 1620
 Gly Ile Ser Thr Ser Ala Thr Thr Asn Leu Lys Cys Ser Leu Leu
 25 1625 1630 1635
 Val Leu Glu Asn Glu Leu Asn Ala Glu Leu Gly Leu Ser Gly Ala
 1640 1645 1650
 Ser Met Lys Leu Thr Thr Asn Gly Arg Phe Arg Glu His Asn Ala
 30 1655 1660 1665
 Lys Phe Ser Leu Asp Gly Lys Ala Ala Leu Thr Glu Leu Ser Leu
 1670 1675 1680
 Gly Ser Ala Tyr Gln Ala Met Ile Leu Gly Val Asp Ser Lys Asn
 35 1685 1690 1695
 Ile Phe Asn Phe Lys Val Ser Gln Glu Gly Leu Lys Leu Ser Asn
 1700 1705 1710
 Asp Met Met Gly Ser Tyr Ala Glu Met Lys Phe Asp His Thr Asn
 37 1715 1720 1725
 Ser Leu Asn Ile Ala Gly Leu Ser Leu Asp Phe Ser Ser Lys Leu
 40 1730 1735 1740
 Asp Asn Ile Tyr Ser Ser Asp Lys Phe Tyr Lys Gln Thr Val Asn
 1745 1750 1755
 Leu Gln Leu Gln Pro Tyr Ser Leu Val Thr Thr Leu Asn Ser Asp
 45 1760 1765 1770
 Leu Lys Tyr Asn Ala Leu Asp Leu Thr Asn Asn Gly Lys Leu Arg
 1775 1780 1785
 Leu Glu Pro Leu Lys Leu His Val Ala Gly Asn Leu Lys Gly Ala
 1790 1795 1800
 Tyr Gln Asn Asn Glu Ile Lys His Ile Tyr Ala Ile Ser Ser Ala
 50 1805 1810 1815
 Ala Leu Ser Ala Ser Tyr Lys Ala Asp Thr Val Ala Lys Val Gln
 1820 1825 1830
 Gly Val Glu Phe Ser His Arg Leu Asn Thr Asp Ile Ala Gly Leu
 55 1835 1840 1845

EP 1 956 029 A1

Ala Ser Ala Ile Asp Met Ser Thr Asn Tyr Asn Ser Asp Ser Leu
 1850 1855 1860

5 His Phe Ser Asn Val Phe Arg Ser Val Met Ala Pro Phe Thr Met
 1865 1870 1875

Thr Ile Asp Ala His Thr Asn Gly Asn Gly Lys Leu Ala Leu Trp
 1880 1885 1890

10 Gly Glu His Thr Gly Gln Leu Tyr Ser Lys Phe Leu Leu Lys Ala
 1895 1900 1905

Glu Pro Leu Ala Phe Thr Phe Ser His Asp Tyr Lys Gly Ser Thr
 1910 1915 1920

15 Ser His His Leu Val Ser Arg Lys Ser Ile Ser Ala Ala Leu Glu
 1925 1930 1935

His Lys Val Ser Ala Leu Leu Thr Pro Ala Glu Gln Thr Gly Thr
 1940 1945 1950

Trp Lys Leu Lys Thr Gln Phe Asn Asn Asn Glu Tyr Ser Gln Asp
 1955 1960 1965

20 Leu Asp Ala Tyr Asn Thr Lys Asp Lys Ile Gly Val Glu Leu Thr
 1970 1975 1980

Gly Arg Thr Leu Ala Asp Leu Thr Leu Leu Asp Ser Pro Ile Lys
 1985 1990 1995

25 Val Pro Leu Leu Leu Ser Glu Pro Ile Asn Ile Ile Asp Ala Leu
 2000 2005 2010

Glu Met Arg Asp Ala Val Glu Lys Pro Gln Glu Phe Thr Ile Val
 2015 2020 2025

30 Ala Phe Val Lys Tyr Asp Lys Asn Gln Asp Val His Ser Ile Asn
 2030 2035 2040

Leu Pro Phe Phe Glu Thr Leu Gln Glu Tyr Phe Glu Arg Asn Arg
 2045 2050 2055

35 Gln Thr Ile Ile Val Val Val Glu Asn Val Gln Arg Asn Leu Lys
 2060 2065 2070

His Ile Asn Ile Asp Gln Phe Val Arg Lys Tyr Arg Ala Ala Leu
 2075 2080 2085

Gly Lys Leu Pro Gln Gln Ala Asn Asp Tyr Leu Asn Ser Phe Asn
 2090 2095 2100

40 Trp Glu Arg Gln Val Ser His Ala Lys Glu Lys Leu Thr Ala Leu
 2105 2110 2115

Thr Lys Lys Tyr Arg Ile Thr Glu Asn Asp Ile Gln Ile Ala Leu
 2120 2125 2130

45 Asp Asp Ala Lys Ile Asn Phe Asn Glu Lys Leu Ser Gln Leu Gln
 2135 2140 2145

Thr Tyr Met Ile Gln Phe Asp Gln Tyr Ile Lys Asp Ser Tyr Asp
 2150 2155 2160

Leu His Asp Leu Lys Ile Ala Ile Ala Asn Ile Ile Asp Glu Ile
 2165 2170 2175

50 Ile Glu Lys Leu Lys Ser Leu Asp Glu His Tyr His Ile Arg Val
 2180 2185 2190

Asn Leu Val Lys Thr Ile His Asp Leu His Leu Phe Ile Glu Asn
 2195 2200 2205

55 Ile Asp Phe Asn Lys Ser Gly Ser Ser Thr Ala Ser Trp Ile Gln
 2210 2215 2220

Asn Val Asp Thr Lys Tyr Gln Ile Arg Ile Gln Ile Gln Glu Lys

EP 1 956 029 A1

	2225		2230		2235							
	Leu Gln	Gln Leu Lys Arg	His Ile Gln Asn Ile	2240	2245	Asp Ile Gln His						
5	Leu Ala	Gly Lys Leu Lys	Gln His Ile Glu Ala	2255	2260	Ile Asp Val Arg						
	Val Leu	Leu Asp Gln Leu	Gly Thr Thr Ile Ser	2270	2275	Phe Glu Arg Ile						
10	Asn Asp	Val Leu Glu His	Val Lys His Phe Val	2285	2290	Ile Asn Leu Ile						
	Gly Asp	Phe Glu Val Ala	Glu Lys Ile Asn Ala	2300	2305	Phe Arg Ala Lys						
15	Val His	Glu Leu Ile Glu	Arg Tyr Glu Val Asp	2315	2320	Gln Gln Ile Gln						
	Val Leu	Met Asp Lys Leu	Val Glu Leu Thr His	2330	2335	Gln Tyr Lys Leu						
20	Lys Glu	Thr Ile Gln Lys	Leu Ser Asn Val Leu	2345	2350	Gln Gln Val Lys						
	Ile Lys	Asp Tyr Phe Glu	Lys Leu Val Gly Phe	2360	2365	Ile Asp Asp Ala						
25	Val Lys	Lys Leu Asn Glu	Leu Ser Phe Lys Thr	2375	2380	Phe Ile Glu Asp						
	Val Asn	Lys Phe Leu Asp	Met Leu Ile Lys Lys	2390	2395	Leu Lys Ser Phe						
30	Asp Tyr	His Gln Phe Val	Asp Glu Thr Asn Asp	2405	2410	Lys Ile Arg Glu						
	Val Thr	Gln Arg Leu Asn	Gly Glu Ile Gln Ala	2420	2425	Leu Glu Leu Pro						
35	Gln Lys	Ala Glu Ala Leu	Lys Leu Phe Leu Glu	2435	2440	Glu Thr Lys Ala						
	Thr Val	Ala Val Tyr Leu	Glu Ser Leu Gln Asp	2450	2455	Thr Lys Ile Thr						
40	Leu Ile	Ile Asn Trp Leu	Gln Glu Ala Leu Ser	2465	2470	Ser Ala Ser Leu						
	Ala His	Met Lys Ala Lys	Phe Arg Glu Thr Leu	2480	2485	Glu Asp Thr Arg						
45	Asp Arg	Met Tyr Gln Met	Asp Ile Gln Gln Glu	2495	2500	Leu Gln Arg Tyr						
	Leu Ser	Leu Val Gly Gln	Val Tyr Ser Thr Leu	2510	2515	Val Thr Tyr Ile						
50	Ser Asp	Trp Trp Thr Leu	Ala Ala Lys Asn Leu	2525	2530	Thr Asp Phe Ala						
	Glu Gln	Tyr Ser Ile Gln	Asp Trp Ala Lys Arg	2540	2545	Met Lys Ala Leu						
55	Val Glu	Gln Gly Phe Thr	Val Pro Glu Ile Lys	2555	2560	Thr Ile Leu Gly						
	Thr Met	Pro Ala Phe Glu	Val Ser Leu Gln Ala	2570	2575	Leu Gln Lys Ala						
	Thr Phe	Gln Thr Pro Asp	Phe Ile Val Pro Leu	2585	2590	Thr Asp Leu Arg						
60	Ile Pro	Ser Val Gln Ile	Asn Phe Lys Asp Leu	2600	2605	Lys Asn Ile Lys						

EP 1 956 029 A1

Ile Pro Ser Arg Phe Ser Thr Pro Glu Phe Thr Ile Leu Asn Thr
 2615 2620 2625
 Phe His Ile Pro Ser Phe Thr Ile Asp Phe Val Glu Met Lys Val
 5 2630 2635 2640
 Lys Ile Ile Arg Thr Ile Asp Gln Met Gln Asn Ser Glu Leu Gln
 2645 2650 2655
 Trp Pro Val Pro Asp Ile Tyr Leu Arg Asp Leu Lys Val Glu Asp
 10 2660 2665 2670
 Ile Pro Leu Ala Arg Ile Thr Leu Pro Asp Phe Arg Leu Pro Glu
 2675 2680 2685
 Ile Ala Ile Pro Glu Phe Ile Ile Pro Thr Leu Asn Leu Asn Asp
 15 2690 2695 2700
 Phe Gln Val Pro Asp Leu His Ile Pro Glu Phe Gln Leu Pro His
 2705 2710 2715
 Ile Ser His Thr Ile Glu Val Pro Thr Phe Gly Lys Leu Tyr Ser
 2720 2725 2730
 Ile Leu Lys Ile Gln Ser Pro Leu Phe Thr Leu Asp Ala Asn Ala
 20 2735 2740 2745
 Asp Ile Gly Asn Gly Thr Thr Ser Ala Asn Glu Ala Gly Ile Ala
 2750 2755 2760
 Ala Ser Ile Thr Ala Lys Gly Glu Ser Lys Leu Glu Val Leu Asn
 25 2765 2770 2775
 Phe Asp Phe Gln Ala Asn Ala Gln Leu Ser Asn Pro Lys Ile Asn
 2780 2785 2790
 Pro Leu Ala Leu Lys Glu Ser Val Lys Phe Ser Ser Lys Tyr Leu
 30 2795 2800 2805
 Arg Thr Glu His Gly Ser Glu Met Leu Phe Phe Gly Asn Ala Ile
 2810 2815 2820
 Glu Gly Lys Ser Asn Thr Val Ala Ser Leu His Thr Glu Lys Asn
 2825 2830 2835
 Thr Leu Glu Leu Ser Asn Gly Val Ile Val Lys Ile Asn Asn Gln
 35 2840 2845 2850
 Leu Thr Leu Asp Ser Asn Thr Lys Tyr Phe His Lys Leu Asn Ile
 2855 2860 2865
 Pro Lys Leu Asp Phe Ser Ser Gln Ala Asp Leu Arg Asn Glu Ile
 40 2870 2875 2880
 Lys Thr Leu Leu Lys Ala Gly His Ile Ala Trp Thr Ser Ser Gly
 2885 2890 2895
 Lys Gly Ser Trp Lys Trp Ala Cys Pro Arg Phe Ser Asp Glu Gly
 45 2900 2905 2910
 Thr His Glu Ser Gln Ile Ser Phe Thr Ile Glu Gly Pro Leu Thr
 2915 2920 2925
 Ser Phe Gly Leu Ser Asn Lys Ile Asn Ser Lys His Leu Arg Val
 50 2930 2935 2940
 Asn Gln Asn Leu Val Tyr Glu Ser Gly Ser Leu Asn Phe Ser Lys
 2945 2950 2955
 Leu Glu Ile Gln Ser Gln Val Asp Ser Gln His Val Gly His Ser
 2960 2965 2970
 Val Leu Thr Ala Lys Gly Met Ala Leu Phe Gly Glu Gly Lys Ala
 55 2975 2980 2985

EP 1 956 029 A1

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55

Glu Phe Thr Gly Arg His Asp Ala His Leu Asn Gly Lys Val Ile
 2990 2995 3000
 Gly Thr Leu Lys Asn Ser Leu Phe Phe Ser Ala Gln Pro Phe Glu
 3005 3010 3015
 Ile Thr Ala Ser Thr Asn Asn Glu Gly Asn Leu Lys Val Arg Phe
 3020 3025 3030
 Pro Leu Arg Leu Thr Gly Lys Ile Asp Phe Leu Asn Asn Tyr Ala
 3035 3040 3045
 Leu Phe Leu Ser Pro Ser Ala Gln Gln Ala Ser Trp Gln Val Ser
 3050 3055 3060
 Ala Arg Phe Asn Gln Tyr Lys Tyr Asn Gln Asn Phe Ser Ala Gly
 3065 3070 3075
 Asn Asn Glu Asn Ile Met Glu Ala His Val Gly Ile Asn Gly Glu
 3080 3085 3090
 Ala Asn Leu Asp Phe Leu Asn Ile Pro Leu Thr Ile Pro Glu Met
 3095 3100 3105
 Arg Leu Pro Tyr Thr Ile Ile Thr Thr Pro Pro Leu Lys Asp Phe
 3110 3115 3120
 Ser Leu Trp Glu Lys Thr Gly Leu Lys Glu Phe Leu Lys Thr Thr
 3125 3130 3135
 Lys Gln Ser Phe Asp Leu Ser Val Lys Ala Gln Tyr Lys Lys Asn
 3140 3145 3150
 Lys His Arg His Ser Ile Thr Asn Pro Leu Ala Val Leu Cys Glu
 3155 3160 3165
 Phe Ile Ser Gln Ser Ile Lys Ser Phe Asp Arg His Phe Glu Lys
 3170 3175 3180
 Asn Arg Asn Asn Ala Leu Asp Phe Val Thr Lys Ser Tyr Asn Glu
 3185 3190 3195
 Thr Lys Ile Lys Phe Asp Lys Tyr Lys Ala Glu Lys Ser His Asp
 3200 3205 3210
 Glu Leu Pro Arg Thr Phe Gln Ile Pro Gly Tyr Thr Val Pro Val
 3215 3220 3225
 Val Asn Val Glu Val Ser Pro Phe Thr Ile Glu Met Ser Ala Phe
 3230 3235 3240
 Gly Tyr Val Phe Pro Lys Ala Val Ser Met Pro Ser Phe Ser Ile
 3245 3250 3255
 Leu Gly Ser Asp Val Arg Val Pro Ser Tyr Thr Leu Ile Leu Pro
 3260 3265 3270
 Ser Leu Glu Leu Pro Val Leu His Val Pro Arg Asn Leu Lys Leu
 3275 3280 3285
 Ser Leu Pro His Phe Lys Glu Leu Cys Thr Ile Ser His Ile Phe
 3290 3295 3300
 Ile Pro Ala Met Gly Asn Ile Thr Tyr Asp Phe Ser Phe Lys Ser
 3305 3310 3315
 Ser Val Ile Thr Leu Asn Thr Asn Ala Glu Leu Phe Asn Gln Ser
 3320 3325 3330
 Asp Ile Val Ala His Leu Leu Ser Ser Ser Ser Ser Val Ile Asp
 3335 3340 3345
 Ala Leu Gln Tyr Lys Leu Glu Gly Thr Thr Arg Leu Thr Arg Lys
 3350 3355 3360
 Arg Gly Leu Lys Leu Ala Thr Ala Leu Ser Leu Ser Asn Lys Phe

EP 1 956 029 A1

		3365					3370						3375			
	Val	Glu	Gly	Ser	His	Asn	Ser	Thr	Val	Ser	Leu	Thr	Thr	Lys	Asn	
		3380					3385					3390				
5	Met	Glu	Val	Ser	Val	Ala	Lys	Thr	Thr	Lys	Ala	Glu	Ile	Pro	Ile	
		3395					3400					3405				
	Leu	Arg	Met	Asn	Phe	Lys	Gln	Glu	Leu	Asn	Gly	Asn	Thr	Lys	Ser	
		3410					3415					3420				
10	Lys	Pro	Thr	Val	Ser	Ser	Ser	Met	Glu	Phe	Lys	Tyr	Asp	Phe	Asn	
		3425					3430					3435				
	Ser	Ser	Met	Leu	Tyr	Ser	Thr	Ala	Lys	Gly	Ala	Val	Asp	His	Lys	
		3440					3445					3450				
15	Leu	Ser	Leu	Glu	Ser	Leu	Thr	Ser	Tyr	Phe	Ser	Ile	Glu	Ser	Ser	
		3455					3460					3465				
	Thr	Lys	Gly	Asp	Val	Lys	Gly	Ser	Val	Leu	Ser	Arg	Glu	Tyr	Ser	
		3470					3475					3480				
20	Gly	Thr	Ile	Ala	Ser	Glu	Ala	Asn	Thr	Tyr	Leu	Asn	Ser	Lys	Ser	
		3485					3490					3495				
	Thr	Arg	Ser	Ser	Val	Lys	Leu	Gln	Gly	Thr	Ser	Lys	Ile	Asp	Asp	
		3500					3505					3510				
25	Ile	Trp	Asn	Leu	Glu	Val	Lys	Glu	Asn	Phe	Ala	Gly	Glu	Ala	Thr	
		3515					3520					3525				
	Leu	Gln	Arg	Ile	Tyr	Ser	Leu	Trp	Glu	His	Ser	Thr	Lys	Asn	His	
		3530					3535					3540				
	Leu	Gln	Leu	Glu	Gly	Leu	Phe	Phe	Thr	Asn	Gly	Glu	His	Thr	Ser	
		3545					3550					3555				
30	Lys	Ala	Thr	Leu	Glu	Leu	Ser	Pro	Trp	Gln	Met	Ser	Ala	Leu	Val	
		3560					3565					3570				
	Gln	Val	His	Ala	Ser	Gln	Pro	Ser	Ser	Phe	His	Asp	Phe	Pro	Asp	
		3575					3580					3585				
35	Leu	Gly	Gln	Glu	Val	Ala	Leu	Asn	Ala	Asn	Thr	Lys	Asn	Gln	Lys	
		3590					3595					3600				
	Ile	Arg	Trp	Lys	Asn	Glu	Val	Arg	Ile	His	Ser	Gly	Ser	Phe	Gln	
		3605					3610					3615				
40	Ser	Gln	Val	Glu	Leu	Ser	Asn	Asp	Gln	Glu	Lys	Ala	His	Leu	Asp	
		3620					3625					3630				
	Ile	Ala	Gly	Ser	Leu	Glu	Gly	His	Leu	Arg	Phe	Leu	Lys	Asn	Ile	
		3635					3640					3645				
	Ile	Leu	Pro	Val	Tyr	Asp	Lys	Ser	Leu	Trp	Asp	Phe	Leu	Lys	Leu	
		3650					3655					3660				
45	Asp	Val	Thr	Thr	Ser	Ile	Gly	Arg	Arg	Gln	His	Leu	Arg	Val	Ser	
		3665					3670					3675				
	Thr	Ala	Phe	Val	Tyr	Thr	Lys	Asn	Pro	Asn	Gly	Tyr	Ser	Phe	Ser	
		3680					3685					3690				
50	Ile	Pro	Val	Lys	Val	Leu	Ala	Asp	Lys	Phe	Ile	Thr	Pro	Gly	Leu	
		3695					3700					3705				
	Lys	Leu	Asn	Asp	Leu	Asn	Ser	Val	Leu	Val	Met	Pro	Thr	Phe	His	
		3710					3715					3720				
55	Val	Pro	Phe	Thr	Asp	Leu	Gln	Val	Pro	Ser	Cys	Lys	Leu	Asp	Phe	
		3725					3730					3735				
	Arg	Glu	Ile	Gln	Ile	Tyr	Lys	Lys	Leu	Arg	Thr	Ser	Ser	Phe	Ala	

EP 1 956 029 A1

	3740		3745		3750							
	Leu Asn	Leu Pro Thr	Leu Pro	Glu Val Lys Phe	Pro Glu Val Asp							
5	3755		3760		3765							
	Val Leu	Thr Lys Tyr Ser	Gln	Pro Glu Asp Ser	Leu Ile Pro Phe							
	3770		3775		3780							
	Phe Glu	Ile Thr Val Pro	Glu	Ser Gln Leu Thr	Val Ser Gln Phe							
	3785		3790		3795							
10	Thr Leu	Pro Lys Ser Val	Ser	Asp Gly Ile Ala	Ala Leu Asp Leu							
	3800		3805		3810							
	Asn Ala	Val Ala Asn Lys	Ile	Ala Asp Phe Glu	Leu Pro Thr Ile							
	3815		3820		3825							
15	Ile Val	Pro Glu Gln Thr	Ile	Glu Ile Pro Ser	Ile Lys Phe Ser							
	3830		3835		3840							
	Val Pro	Ala Gly Ile Val	Ile	Pro Ser Phe Gln	Ala Leu Thr Ala							
	3845		3850		3855							
20	Arg Phe	Glu Val Asp Ser	Pro	Val Tyr Asn Ala	Thr Trp Ser Ala							
	3860		3865		3870							
	Ser Leu	Lys Asn Lys Ala	Asp	Tyr Val Glu Thr	Val Leu Asp Ser							
	3875		3880		3885							
	Thr Cys	Ser Ser Thr Val	Gln	Phe Leu Glu Tyr	Glu Leu Asn Val							
	3890		3895		3900							
25	Leu Gly	Thr His Lys Ile	Glu	Asp Gly Thr Leu	Ala Ser Lys Thr							
	3905		3910		3915							
	Lys Gly	Thr Leu Ala His	Arg	Asp Phe Ser Ala	Glu Tyr Glu Glu							
	3920		3925		3930							
30	Asp Gly	Lys Phe Glu Gly	Leu	Gln Glu Trp Glu	Gly Lys Ala His							
	3935		3940		3945							
	Leu Asn	Ile Lys Ser Pro	Ala	Phe Thr Asp Leu	His Leu Arg Tyr							
	3950		3955		3960							
35	Gln Lys	Asp Lys Lys Gly	Ile	Ser Thr Ser Ala	Ala Ser Pro Ala							
	3965		3970		3975							
	Val Gly	Thr Val Gly Met	Asp	Met Asp Glu Asp	Asp Asp Phe Ser							
	3980		3985		3990							
40	Lys Trp	Asn Phe Tyr Tyr	Ser	Pro Gln Ser Ser	Pro Asp Lys Lys							
	3995		4000		4005							
	Leu Thr	Ile Phe Lys Thr	Glu	Leu Arg Val Arg	Glu Ser Asp Glu							
	4010		4015		4020							
	Glu Thr	Gln Ile Lys Val	Asn	Trp Glu Glu Glu	Ala Ala Ser Gly							
	4025		4030		4035							
45	Leu Leu	Thr Ser Leu Lys	Asp	Asn Val Pro Lys	Ala Thr Gly Val							
	4040		4045		4050							
	Leu Tyr	Asp Tyr Val Asn	Lys	Tyr His Trp Glu	His Thr Gly Leu							
	4055		4060		4065							
50	Thr Leu	Arg Glu Val Ser	Ser	Lys Leu Arg Arg	Asn Leu Gln Asn							
	4070		4075		4080							
	Asn Ala	Glu Trp Val Tyr	Gln	Gly Ala Ile Arg	Gln Ile Asp Asp							
	4085		4090		4095							
	Ile Asp	Val Arg Phe Gln	Lys	Ala Ala Ser Gly	Thr Thr Gly Thr							
	4100		4105		4110							
55	Tyr Gln	Glu Trp Lys Asp	Lys	Ala Gln Asn Leu	Tyr Gln Glu Leu							
	4115		4120		4125							

EP 1 956 029 A1

5 Leu Thr Gln Glu Gly Gln Ala Ser Phe Gln Gly Leu Lys Asp Asn
 4130 4135 4140
 Val Phe Asp Gly Leu Val Arg Val Thr Gln Lys Phe His Met Lys
 4145 4150 4155
 Val Lys His Leu Ile Asp Ser Leu Ile Asp Phe Leu Asn Phe Pro
 4160 4165 4170
 10 Arg Phe Gln Phe Pro Gly Lys Pro Gly Ile Tyr Thr Arg Glu Glu
 4175 4180 4185
 Leu Cys Thr Met Phe Ile Arg Glu Val Gly Thr Val Leu Ser Gln
 4190 4195 4200
 Val Tyr Ser Lys Val His Asn Gly Ser Glu Ile Leu Phe Ser Tyr
 4205 4210 4215
 15 Phe Gln Asp Leu Val Ile Thr Leu Pro Phe Glu Leu Arg Lys His
 4220 4225 4230
 Lys Leu Ile Asp Val Ile Ser Met Tyr Arg Glu Leu Leu Lys Asp
 4235 4240 4245
 20 Leu Ser Lys Glu Ala Gln Glu Val Phe Lys Ala Ile Gln Ser Leu
 4250 4255 4260
 Lys Thr Thr Glu Val Leu Arg Asn Leu Gln Asp Leu Leu Gln Phe
 4265 4270 4275
 25 Ile Phe Gln Leu Ile Glu Asp Asn Ile Lys Gln Leu Lys Glu Met
 4280 4285 4290
 Lys Phe Thr Tyr Leu Ile Asn Tyr Ile Gln Asp Glu Ile Asn Thr
 4295 4300 4305
 30 Ile Phe Asn Asp Tyr Ile Pro Tyr Val Phe Lys Leu Leu Lys Glu
 4310 4315 4320
 Asn Leu Cys Leu Asn Leu His Lys Phe Asn Glu Phe Ile Gln Asn
 4325 4330 4335
 Glu Leu Gln Glu Ala Ser Gln Glu Leu Gln Gln Ile His Gln Tyr
 4340 4345 4350
 35 Ile Met Ala Leu Arg Glu Glu Tyr Phe Asp Pro Ser Ile Val Gly
 4355 4360 4365
 Trp Thr Val Lys Tyr Tyr Glu Leu Glu Glu Lys Ile Val Ser Leu
 4370 4375 4380
 40 Ile Lys Asn Leu Leu Val Ala Leu Lys Asp Phe His Ser Glu Tyr
 4385 4390 4395
 Ile Val Ser Ala Ser Asn Phe Thr Ser Gln Leu Ser Ser Gln Val
 4400 4405 4410
 45 Glu Gln Phe Leu His Arg Asn Ile Gln Glu Tyr Leu Ser Ile Leu
 4415 4420 4425
 Thr Asp Pro Asp Gly Lys Gly Lys Glu Lys Ile Ala Glu Leu Ser
 4430 4435 4440
 Ala Thr Ala Gln Glu Ile Ile Lys Ser Gln Ala Ile Ala Thr Lys
 4445 4450 4455
 50 Lys Ile Ile Ser Asp Tyr His Gln Gln Phe Arg Tyr Lys Leu Gln
 4460 4465 4470
 Asp Phe Ser Asp Gln Leu Ser Asp Tyr Tyr Glu Lys Phe Ile Ala
 4475 4480 4485
 55 Glu Ser Lys Arg Leu Ile Asp Leu Ser Ile Gln Asn Tyr His Thr
 4490 4495 4500

5 Phe Leu Ile Tyr Ile Thr Glu Leu Leu Lys Lys Leu Gln Ser Thr
 4505 4510 4515

Thr Val Met Asn Pro Tyr Met Lys Leu Ala Pro Gly Glu Leu Thr
 4520 4525 4530

Ile Ile Leu
 4535

10 <210> 2
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 2

15 Val Pro Ser Cys Lys Leu Asp Phe Arg Glu
 1 5 10

20

Claims

- 25 1. A predicting factor for vascular aging comprising an apolipoprotein B100 having a glutathionylated thiol group, or a part thereof which includes the glutathionylated region and consists of at least 10 amino acid residues.
- 30 2. The predicting factor of claim 1, wherein the apolipoprotein B100 and a part thereof include at least an amino acid sequence represented by SEQ ID NO: 2, wherein the glutathionylated region is a thiol group of a cysteine in the amino acid sequence.
- 35 3. A method for examining a lesion resulting from vascular aging comprising measurement of an apolipoprotein B100 having a glutathionylated thiol group using a biological sample.
- 40 4. The method of claim 3, wherein the biological sample is blood.
- 45 5. The method of claim 3 or 4, wherein the lesion resulting from vascular aging is accompanied by a disorder selected from the group consisting of diabetes mellitus, cerebrovascular disorder, cardiovascular disorder, obstructive arteriosclerosis, dementia, atherosclerosis, hypertension, obesity, and the like.
- 50 6. An antibody specifically recognizing an apolipoprotein B100 having a glutathionylated thiol group, or a part thereof which includes the glutathionylated region, and consists of at least 10 amino acid residues.
- 55 7. An antibody specifically recognizing glutathionylation of a thiol group of a cysteine in an amino acid sequence represented by SEQ ID NO: 2.
8. A diagnostic agent or a diagnostic kit for a lesion resulting from vascular aging comprising an antibody specifically recognizing an apolipoprotein B100 having a glutathionylated thiol group.

FIG. 1




FIG. 2




FIG. 3





FIG. 4

(A)



(B)





FIG. 5

(A)



(B)





FIG. 6

thiol reductase activity



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2006/321610

A. CLASSIFICATION OF SUBJECT MATTER C07K14/47(2006.01) i, C07K16/18(2006.01) i, G01N33/53(2006.01) i		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) C07K14/47, C07K16/18, G01N33/53		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2006 Kokai Jitsuyo Shinan Koho 1971-2006 Toroku Jitsuyo Shinan Koho 1994-2006		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) BIOSIS/MEDLINE/WPIDS (STN), CA (STN), Science Direct, JMEDPlus (JDreamII), JSTPlus (JDreamII)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	YANG CY, et al., Selective modification of apoB-100 in the oxidation of low density lipoproteins by myeloperoxidase in vitro., J Lipid Res., 1999, vol.40, no.4, p.686-698	1-8
A	YANG CY, et al., Oxidative modifications of apoB-100 by exposure of low density lipoproteins to HOCL in vitro., Free Radic Biol Med., 1997, vol.23, no.1, p.82-89	1-8
X/A	VAN ANTWERPEN P, et al., Thiol-containing molecules interact with the myeloperoxidase/H2O2/chloride system to inhibit LDL oxidation., Biochem Biophys Res Commun., 2005 Nov 11, vol.337, no.1, p.82-88	1,2/3-8
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 11 December, 2006 (11.12.06)		Date of mailing of the international search report 19 December, 2006 (19.12.06)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2006/321610

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHENG G, et al., Detection of S-glutathionylated proteins by glutathione S-transferase overlay., Arch Biochem Biophys., 2005 Mar 1, vol.435, no.1, p.42-49	1-8
A	LIND C, et al., Identification of S-glutathionylated cellular proteins during oxidative stress and constitutive metabolism by affinity purification and proteomic analysis., Arch Biochem Biophys., 2002, vol. 406, no.2, p.229-240	1-8
A	KLATTt P, et al., Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress., Eur J Biochem., 2000, vol.267, no.16, p.4928-4944	1-8

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- JP H0373280 B [0048]
- JP H04506458 T [0048]
- JP 62296890 A [0048]
- JP H04504365 T [0048]
- WO 9425585 A [0048]
- JP H06500233 T [0048]
- JP 2005344630 A [0070]

Non-patent literature cited in the description

- **HEILLE, OP et al.** *Eur. J. Neurosci.*, 1994, vol. 6, 793-804 [0005]
- **CHENG, G et al.** *Archiv. Biochem. Biophys.*, 2005, vol. 435, 42-49 [0005]
- *Exp. Opin. Ther. Patents*, 1996, vol. 6 (5), 441-456 [0031]
- **KOHLER ; MILLSTEIN.** *Nature*, 1975, vol. 256, 495-497 [0042]
- *Experimental Medicine*. 1988, vol. 6 [0048]
- *Nature Genetics*, 1997, vol. 15, 146-156 [0048]
- *Nature Genetics*, 1994, vol. 7, 13-21 [0048]
- *Nikkei Science*, June 1995, 40-50 [0048]
- *Nature*, 1994, vol. 368, 856-859 [0048]
- **SUSANNE MOHR et al.** *Journal of Biological Chemistry*, 1999, vol. 274 (14), 9427-9430 [0055]
- **HJELLE O. P. et al.** *Eur. J. Neurosci.*, 1994, vol. 6 (5), 793-804 [0055]
- **CHENG G et al.** *Archives of Biochemistry and Biophysics*, 2005, vol. 435, 42-49 [0055]
- **CUSHING SD et al.** *Proc. Natl. Acad. Sci. USA*, 1990, vol. 87, 5134-5138 [0057]
- **KANDA, M ; KONDO, T. et al.** *J. Biol. Chem.*, 2006, vol. 281 (39), 28518-28528 [0068]

专利名称(译)	血管老化预测因子及其利用率		
公开(公告)号	EP1956029A4	公开(公告)日	2010-10-06
申请号	EP2006822567	申请日	2006-10-30
申请(专利权)人(译)	长崎大学		
当前申请(专利权)人(译)	长崎大学		
[标]发明人	KONDO TAKAHITO IHARA YOSHIHITO URATA YOSHISHIGE GOTO SHINJI KONO TAKAAKI		
发明人	KONDO, TAKAHITO IHARA, YOSHIHITO URATA, YOSHISHIGE GOTO, SHINJI KONO, TAKAAKI		
IPC分类号	C07K14/47 C07K16/18 G01N33/53		
CPC分类号	G01N33/6893 C07K14/775 C07K16/18 G01N2800/32		
优先权	2005344630 2005-11-29 JP		
其他公开文献	EP1956029A1		
外部链接	Espacenet		

摘要(译)

提供了血管老化的预测因子和由血管老化引起的早期病变的检查方法。具体地，血管老化的预测因子包括具有谷胱甘肽化硫醇基的人载脂蛋白B100;检查由血管老化引起的病变的方法包括测量血样中具有谷胱甘肽化硫醇基的人载脂蛋白B100;特异性识别具有谷胱甘肽化硫醇基的载脂蛋白B100的抗体;本发明提供了一种诊断剂或诊断试剂盒，用于由血管老化引起的早期病变，其含有识别具有谷胱甘肽化硫基的人载脂蛋白B100的抗体。